ライフサイエンスコーパス: pneumoniae

1 ase-negative Staphylococcus, 1 Streptococcus pneumoniae).

2 elopment of therapeutics for treatment of S. pneumoniae.

3 y mucus and the human pathogen Streptococcus pneumoniae.

4 tified organism on culture was Streptococcus pneumoniae.

5 nsusceptible, ompK36 porin mutant Klebsiella pneumoniae.

6 h for Acinetobacter baumannii and Klebsiella pneumoniae.

7 for all classes, both for E. coli and for K. pneumoniae.

8 n waves defining competence in Streptococcus pneumoniae.

9 ems in 259 clinically relevant genomes of K. pneumoniae.

10 xpression control on the pathogenicity of S. pneumoniae.

11 escued mice 3 months after challenge with S. pneumoniae.

12 ri, Moraxella catarrhalis, and Streptococcus pneumoniae.

13 ) controls were infected intranasally with S pneumoniae.

14 cine against the K2 sero group of Klebsiella pneumoniae.

15 tion with Escherichia coli and Streptococcus pneumoniae.

16 cal impact and infected intranasally with S. pneumoniae (1,500 colony-forming units) or vehicle (phos

17 e was found with Streptococcus pneumoniae (S pneumoniae) 1.2% (0.8-1.6) and Spyogenes 1.9% (0.9-3.3).

18 6; 2 group B Streptococcus; 2 Streptococcus pneumoniae; 1 HSV; 1 parechovirus; 1 enterovirus) and 2

19 coccus aureus (34/37 [91.9%]), Streptococcus pneumoniae (10/11 [90.9%]), and Enterobacter cloacae com

20 st common baseline pathogens were Klebsiella pneumoniae (25.6%) and Pseudomonas aeruginosa (18.9%).

21 erpes simplex virus (HSV), and 6% Mycoplasma pneumoniae; 25% (95% CI, 20%-30%) had immune-mediated en

22 od cultures most commonly grew Streptococcus pneumoniae (33%), followed by S. aureus (22%).

23 Furthermore, K. pneumoniae 51-5 induces DNA damage and cell cycle arrest

24 bsiella pneumoniae (86 [31%]), Streptococcus pneumoniae (54 [20%]), HIV (40 [15%]), and cytomegalovir

25 was most common in macrolide-susceptible M. pneumoniae (67.5%).

26 ommon contributory pathogens were Klebsiella pneumoniae (86 [31%]), Streptococcus pneumoniae (54 [20%

27 Streptococcus pneumoniae (9/44 [20%]) and Staphylococcus aureus (7/14

28 The most common pathogens were Streptococcus pneumoniae (93 of 143, 65%) and Haemophilus influenzae (

29 verse-engineer gene expression control in S. pneumoniae A selection platform is described that allows

30 Klebsiella pneumoniae, a Gram-negative bacterium, is notorious for

31 y, encompassing Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aerugino

32 s faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aerugin

33 signaling in neutrophils is essential for K. pneumoniae-activated ROS production and for promoting ba

34 n among this small selection of isolates, K. pneumoniae adopts differing mechanisms and utilizes dist

35 these genes encode proteins that protect K. pneumoniae against neutrophil-related effector functions

36 ized the effects of these two peptides on K. pneumoniae, along with their physical interactions with

37 M. pneumoniae also bound lactose 3'-sulfate ligated to an i

38 Such has been the case with Streptococcus pneumoniae, an important human pathogen, and the pneumoc

39 ansmission and pathogenesis of Streptococcus pneumoniae, an opportunistic human-adapted pathogen, is

40 (91% sensitivity and 100% specificity for S. pneumoniae and 81% sensitivity and 100% specificity for

41 lates of Acinetobacter baumannii, Klebsiella pneumoniae and E. coli.

42 ied pathogenic bacteria (that is, Klebsiella pneumoniae and Enterobacter cloacae) and their correspon

43 Klebsiella pneumoniae and Escherichia coli are part of the Enteroba

44 Predominant causative pathogens are S. pneumoniae and H. influenzae.

45 he pathobiology and epidemicity of Kpi(+) K. pneumoniae and indicate that the presence of Kpi may exp

46 conserved in pathogens such as Streptococcus pneumoniae and Mycobacterium tuberculosis AtaC is monome

47 bility and resistance for both Streptococcus pneumoniae and Neisseria gonorrhoeae.

48 r than observed over longer timescales in S. pneumoniae and other bacteria drives high within-host pn

49 ntial during infection with A. baumannii, K. pneumoniae and P. aeruginosa.

50 such as Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa.

51 ical consolidation or pleural fluid, with S. pneumoniae and S. aureus the leading pathogens identifie

52 d with influenza or bacterial (Streptococcus pneumoniae and Staphylococcus aureus) etiologies and com

53 Common causative organisms are Streptococcus pneumoniae and Staphylococcus aureus.

54 fection by Escherichia coli or Streptococcus pneumoniae) and endotoxaemia.

55 s, specific antibodies against Streptococcus pneumoniae, and allergen-specific IgE, as well as detail

56 iotic activity over AZ1 against wild-type K. pneumoniae, and coadministration with outer membrane per

57 ia coli, Pseudomonas syringae and Klebsiella pneumoniae, and endogenous CRISPR-Cas use was enhanced w

58 stant Enterococcus faecium (VRE), Klebsiella pneumoniae, and Escherichia coli in the intestinal lumen

59 A and B, Bordetella pertussis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae This multicenter e

60 Streptococcus anginosus group, Streptococcus pneumoniae, and Streptococcus pyogenes), positive percen

61 ; pneumonia (viral, bacterial, Streptococcus pneumoniae, and unspecified pneumonia); influenza; tuber

62 ted Streptococcus pyogenes and Streptococcus pneumoniae, and while research on GBS TCSs has been incr

63 Importantly, C. trachomatis and C. pneumoniae are Trp auxotrophs and are starved for this e

64 In multivariable analysis using S pneumoniae as reference, all species except S pyogenes w

65 Mycoplasma pneumoniae ASCs measured by enzyme-linked immunospot ass

66 Mycoplasma pneumoniae ASCs of the isotype IgM were found in 29 (46%

67 Mycoplasma pneumoniae ASCs were detected from 2 days to a maximum o

68 Mycoplasma pneumoniae ASCs were undetectable in HCs, in contrast to

69 f the hospital environment as a source of K. pneumoniae associated with serious human infection.

70 SKAP2, is required for protection against K. pneumoniae (ATCC 43816) pulmonary infections.

71 inflammation during AA and the control of S. pneumoniae bacterial disease.

72 MDR) carbapenemase-producing (CP) Klebsiella pneumoniae, belonging to clonal group CG258, is capable

73 ctosylceramide) to provide a baseline for M. pneumoniae binding and gliding motility.

74 As expected, M. pneumoniae bound to surfaces coated with sulfatide in a

75 ringens, Ruminococcus gnavus, and Klebsiella pneumoniae, but also beneficial species, such as Faecali

76 arker for GI colonization, we showed that K. pneumoniae can asymptomatically colonize the GI tract in

77 e escape in the human pathogen Streptococcus pneumoniae can be largely attributed to competence-induc

78 Streptococcus pneumoniae can cause disease in various human tissues an

79 We demonstrate that K. pneumoniae can enhance its pathogenicity by adopting two

80 In the latter case, drug-tolerant K. pneumoniae can persist to yield potentially untreatable,

81 tanding the epidemiology of nonbacteremic S. pneumoniae CAP and for assessing the efficacy of future

82 aggregation, leading to disruption of the K. pneumoniae capsule.

83 ong with their physical interactions with K. pneumoniae capsule.

84 Klebsiella pneumoniae carbapenemase (KPC) is a widespread SBL that

85 r genotypic profiles, whereas all Klebsiella pneumoniae carbapenemase (KPC; n = 8) and GES (n = 12) i

86 nterobacter sp. isolate producing Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-beta-La

87 ce and clinical impact of a novel Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-KP

88 , but the impact of viruses on Streptococcus pneumoniae carriage prevalence and load remains poorly u

89 Furthermore, K. pneumoniae carrier mice were able to transmit to uninfec

90 The genomes of K pneumoniae carrying bla(NDM) and bla(KPC) were sequenced

91 xually transmitted infections, and Chlamydia pneumoniae causes community-acquired respiratory infecti

92 Klebsiella pneumoniae causes pneumonia and liver abscesses in human

93 egulon can therefore be utilized to study S. pneumoniae cell-cell communication and behavioral change

94 hydrolase CbpD that targets the septum of S. pneumoniae cells to show that class A PBPs have an auton

95 The local K pneumoniae CG258 population was dominated by sequence ty

96 ur findings show that effective control of K pneumoniae CG258 with bacteriophage will require mixes o

97 Streptococcus pneumoniae choline kinase (sChoK) has previously been pr

98 w commensal Bacteroidetes protect against K. pneumoniae colonization and contagion, providing insight

99 the upper airways and intestine to limit K. pneumoniae colonization within these niches.

100 ccus sanguinis (ComGC(SS)) and Streptococcus pneumoniae (ComGC(SP)), revealing that this pilin displa

101 nd 23F, covered by the licensed 13-valent S. pneumoniae conjugate vaccine.

102 regional clinical concern, e.g., Klebsiella pneumoniae contigs containing KPC-2 within an ISKpn6-lik

103 ns caused by carbapenem-resistant Klebsiella pneumoniae continues to be challenging.

104 ecific IgGs in serum, the newly developed S. pneumoniae CPS microarrays offer the advantage of enabli

105 ing a collection of 22 microarray-printed S. pneumoniae CPSs.

106 UAT more often had a positive Streptococcus pneumoniae culture (25.4% vs 1.9%, P < .001) and less of

107 ua, Pseudomonas aeruginosa and Streptococcus pneumoniae did not interfere the detection results.

108 ecific qPCR tests targeting S. aureus and S. pneumoniae did not provide additional diagnoses but prov

109 egulation of airway barrier integrity and S. pneumoniae disease.

110 tion of host and bacterial factors toward K. pneumoniae dissemination.

111 gonism between the microbiota and Klebsiella pneumoniae during colonization and transmission.

112 However, knowledge of K. pneumoniae ecology, population structure or pathogenicit

113 roptosis inhibition reduced the number of S. pneumoniae foci observed in hearts of acutely infected m

114 (75% sensitivity and 100% specificity for S. pneumoniae) for clinical metagenomic sputum samples.

115 We included 88 patients with PR K. pneumoniae from 2011-2018 and collected demographic, ant

116 We conducted cross-sectional surveys of K. pneumoniae from 29 livestock farms, 97 meat products, th

117 aeruginosa, Escherichia coli, and Klebsiella pneumoniae from resin-containing BacT/Alert FA Plus and

118 ridge, United Kingdom, in 2015 to isolate K. pneumoniae from stool, blood, and the environment.

119 The qPCR tests targeting S. aureus and S. pneumoniae gave earlier results than culture and panbact

120 d opportunistic human pathogen Streptococcus pneumoniae generates large amounts of hydrogen peroxide

121 To investigate the M. pneumoniae genotype shift and its impact on clinical pre

122 Consistent with this conclusion, the M. pneumoniae HA-negative mutant II-3 failed to bind to sia

123 ired infections caused by 'hypervirulent' K. pneumoniae has also emerged, associated with strains exp

124 Carbapenemase-producing Klebsiella pneumoniae has become a global priority, not least in lo

125 K. pneumoniae has become an increasing concern due to the r

126 f these infections difficult to treat, as K. pneumoniae has become multidrug resistant.

127 Over the past decade, K. pneumoniae has emerged as a major clinical and public he

128 Previous studies in Streptococcus pneumoniae have shown that hsdS inversions within clonal

129 , but P1-specific antibodies that blocked M. pneumoniae hemadsorption (HA) and binding to the sialyla

130 Epidemiological studies suggest that K. pneumoniae host-to-host transmission requires close cont

131 es a general strategy to block Streptococcus pneumoniae IgA1 protease activity to potentially prevent

132 rticle reconstructions how the Streptococcus pneumoniae IgA1 protease facilitates IgA1 substrate reco

133 Specifically, the Streptococcus pneumoniae IgA1 protease subscribes to an active-site-ga

134 concomitant with either positive Mycoplasma pneumoniae IgM or PCR testing from January 1, 2010, unti

135 involved in regulating the endocytosis of C. pneumoniae in an EGFR- and SNX9-dependent manner.

136 ts asymptomatic nasopharyngeal carriage of S pneumoniae in mice, leading to dissemination to lungs an

137 various immune responses to live Mycoplasma pneumoniae in SP-A knockout mice and RAW 264.7 cells.

138 mercial molecular assays for detection of M. pneumoniae in the United States and identified clear dif

139 vnar-13) against the bacterium Streptococcus pneumoniae induced immune responses that were similar to

140 K. pneumoniae-induced neutrophil ROS response required the

141 loss of SKAP2 significantly hindered the K. pneumoniae-induced phosphorylation of SFKs, Syk, and Pyk

142 iver and spleen and were more susceptible K. pneumoniae-induced sepsis.

143 lity rate, in contrast to no mortality in S. pneumoniae-infected sham (Sham + Sp) animals.

144 At 3 days post-injury, S. pneumoniae-infected traumatic brain injury mice (TBI + S

145 no evidence for livestock as a source of K. pneumoniae infecting humans.

146 Streptococcus pneumoniae infection can result in bacteremia with devas

147 mice are better protected from Streptococcus pneumoniae infection due to a population of monocyte-der

148 ct model followed by secondary Streptococcus pneumoniae infection in mice.

149 hils degranulated normally in response to K. pneumoniae infection in mice; however, K. pneumoniae-sti

150 Secondary Streptococcus pneumoniae infection is a significant cause of morbidity

151 We have previously shown that S. pneumoniae infection of the respiratory epithelium induc

152 remia with Escherichia coli or Streptococcus pneumoniae infection).

153 d an effect on p38 phosphorylation during M. pneumoniae infection, the 223Q-20mer peptide significant

154 ured mice had greater mortality following S. pneumoniae infection, which suggests that respiratory in

155 onfer population-level protection against K. pneumoniae infection.

156 ison to the 20-mer containing 223K during M. pneumoniae infection.

157 ty in reducing TNF-alpha induction during M. pneumoniae infection.

158 s and exaggerated responses to Streptococcus pneumoniae infection.

159 re a promising drug lead scaffold against S. pneumoniae infections that could be administered individ

160 uld inform new approaches to treatment of K. pneumoniae infections.

161 behavioral changes, as well as attenuate S. pneumoniae infectivity.

162 Mycoplasma pneumoniae is a cell wall-less bacterial pathogen of the

163 Klebsiella pneumoniae is a common cause of antibiotic-resistant pne

164 Klebsiella pneumoniae is a common cause of antimicrobial-resistant

165 Streptococcus pneumoniae is a devastating global pathogen.

166 SP_0782 from Streptococcus pneumoniae is a dimeric protein that potentially binds w

167 Klebsiella pneumoniae is a Gram-negative bacterial pathogen that ca

168 Klebsiella pneumoniae is a human, animal, and environmental commens

169 Streptococcus pneumoniae is a leading cause of pneumonia among childre

170 Streptococcus pneumoniae is a major cause of community-acquired pneumo

171 Mycoplasma pneumoniae is a major cause of community-acquired pneumo

172 Streptococcus pneumoniae is a major cause of pneumonia, wherein infect

173 Streptococcus pneumoniae is a major human pathogen that must adapt to

174 Streptococcus pneumoniae is a major respiratory pathogen, causing noni

175 Streptococcus pneumoniae is a natural colonizer of the human respirato

176 Klebsiella pneumoniae is a respiratory, blood, liver, and bladder p

177 Streptococcus pneumoniae is a significant cause of otitis media, pneum

178 Streptococcus pneumoniae is an opportunistic human pathogen that cause

179 Streptococcus pneumoniae is an opportunistic human pathogen that utili

180 is found at bacterial entry sites, where C. pneumoniae is internalized via EGFR-mediated endocytosis

181 Streptococcus pneumoniae is one of the world's leading bacterial patho

182 Streptococcus pneumoniae is responsible for severe infections, causing

183 le in the pathobiology and epidemicity of K. pneumoniae is therefore important for managing infection

184 , we studied a carbapenem-resistant ST-15 K. pneumoniae isolate (Kp3380) that displayed a remarkable

185 A hypervirulent K. pneumoniae isolate was able to translocate from the GI t

186 , carbapenemase (KPC-3)-producing Klebsiella pneumoniae isolate.

187 ospitalized adults with liver abscess and K. pneumoniae isolated from blood or abscess fluid who had

188 - and short-read sequence data of Klebsiella pneumoniae isolates (n = 1,717) from a European survey t

189 ular mechanisms leading to PR in clinical K. pneumoniae isolates are remarkably heterogenous, even wi

190 among the Enterobacterales (for 2 Klebsiella pneumoniae isolates).

191 ultures growing Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, or Proteus mirabilis at

192 ere infected intratracheally with Klebsiella pneumoniae (KP) and assessed for extrapulmonary dissemin

193 siella pneumoniae carbapenemase-producing K. pneumoniae (KPC-KP) sequence type (ST) 16 clone in a clo

194 Klebsiella pneumoniae liver abscess (KLA) is emerging worldwide due

195 e report the crystal structure of Klebsiella pneumoniae LpxH in complex with AZ1.

196 FSTL-1 Hypo mice had reduced K. pneumoniae lung burden compared with that of WT controls

197 the host response to AA protected against S. pneumoniae lung disease, the IL-6 deficiency abrogated t

198 The epidemiology of Mycoplasma pneumoniae (Mp) among US children (<18 years) hospitaliz

199 ns or symptoms that differentiate Mycoplasma pneumoniae (Mp) infection in community-acquired pneumoni

200 onstrated that the measurement of Mycoplasma pneumoniae (Mp)-specific immunoglobulin (Ig)M antibody-s

201 Macrolide-resistant M. pneumoniae (MRMp) was detected in 37 (8.3%) specimens.

202 We conducted phylogenetic analyses of key K. pneumoniae multi-locus sequence types (ST258, ST17, ST30

203 We show that a PLY-deficient S. pneumoniae mutant was impaired in triggering human neutr

204 Insertions in 166 genes resulted in K. pneumoniae mutants that were significantly less fit in t

205 For Klebsiella pneumoniae, Mycobacterium tuberculosis, Salmonella enter

206 svirus 6 (HHV-6) (n = 30), and Streptococcus pneumoniae (n = 14).

207 detected by the Carba-R assay in Klebsiella pneumoniae (n = 236), Escherichia coli (n = 22), Enterob

208 uctural envelope of SpNOX, the Streptococcus pneumoniae NADPH oxidase (NOX), a prokaryotic model syst

209 mercial molecular tests targeting Mycoplasma pneumoniae, namely, the BioFire FilmArray respiratory pa

210 to increased carriage of nonencapsulated S. pneumoniae (NESp).

211 tely, we find that host-to-host spread of K. pneumoniae occurs principally from its intestinal reserv

212 onsisting of Escherichia coli and Klebsiella pneumoniae once antibiotics were removed.

213 ore likely to be infected with Chlamydophila pneumoniae or Staphylococcus aureus, have received antib

214 cteria prime immunity through IL-17A, but K. pneumoniae overcomes these defences through encapsulatio

215 e effect of allergic inflammation against S. pneumoniae pathogenesis.

216 ional structure of the related Streptococcus pneumoniae PBP2X suggests that some substitutions are lo

217 Streptococcus pneumoniae (Pnc) serotypes differ in invasive potential.

218 Streptococcus pneumoniae (pneumococcus) is a leading cause of infectio

219 Streptococcus pneumoniae (pneumococcus) is a principal cause of bacter

220 ride conjugate vaccine against Streptococcus pneumoniae (pneumococcus).

221 instigated by pore-forming toxins such as S. pneumoniae pneumolysin.

222 Analysis of a large K. pneumoniae population from 32 European countries showed

223 A deeper understanding of K. pneumoniae population structure and diversity will be im

224 ristics of M. pneumoniae We collected 446 M. pneumoniae-positive specimens from 9 states between Augu

225 Intestinal colonization with K. pneumoniae, Proteus mirabilis, or Enterobacter cloacae p

226 M. pneumoniae recognizes sialylated and sulfated oligosacch

227 cerns have stimulated renewed interest in K. pneumoniae research and particularly the application of

228 phenotype of Escherichia coli and Klebsiella pneumoniae, resistant to piperacillin/tazobactam (TZP) b

229 ellular polysaccharide capsule of Klebsiella pneumoniae resists penetration by antimicrobials and pro

230 (S. aureus) or Streptococcus pneumoniae (S. pneumoniae), respectively; and a qPCR assay targeting th

231 hanism behind this interaction related to S. pneumoniae respiratory illnesses.

232 of pathogenicity in carbapenem-resistant K. pneumoniae, resulting in the repeated convergence of vir

233 Haemophilus influenzae type b, Streptococcus pneumoniae, rotavirus, measles, meningitis A, rubella, a

234 t IE prevalence was found with Streptococcus pneumoniae (S pneumoniae) 1.2% (0.8-1.6) and Spyogenes 1

235 lococcus aureus (S. aureus) or Streptococcus pneumoniae (S. pneumoniae), respectively; and a qPCR ass

236 pportunistic pathogens such as Streptococcus pneumoniae secrete a giant metalloprotease virulence fac

237 During invasion of host cells, Chlamydia pneumoniae secretes the effector protein CPn0678, which

238 In oval-shaped Streptococcus pneumoniae, septal and longitudinal peptidoglycan synthe

239 We identified ICEKp2 in K. pneumoniae sequence types ST11, ST258 and ST512, which a

240 Streptococcus pneumoniae serotype 1 is the predominant cause of invasi

241 for Shigella sonnei O-antigen, Streptococcus pneumoniae serotype 12F, and Staphylococcus aureus types

242 coccal disease (IPD) caused by Streptococcus pneumoniae serotype 2 (Sp2) is infrequent.

243 Here, we show that a S. pneumoniae serotype 6B ST90 strain, which does not cause

244 In addition, the UAD-2 assay identified a S. pneumoniae serotype in 3.72% of nonbacteremic CAP cases

245 lar polysaccharide of a dominated Klebsiella pneumoniae serotype K2 is difficult to synthesize chemic

246 t the capsular polysaccharide (CPS) offer S. pneumoniae serotype-specific protection.

247 first described a UAD assay to detect the S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C

248 Identifying Streptococcus pneumoniae serotypes by urinary antigen detection (UAD)

249 radiographically confirmed CAP caused by S. pneumoniae serotypes in hospitalized US adults.

250 The Klebsiella pneumoniae species complex includes important opportunis

251 Mycoplasma pneumoniae-specific ASCs are short-lived and associated

252 tercepting the competence regulon in both S. pneumoniae specificity groups with activities at the low

253 Streptococcus pneumoniae (Spn) colonizes the nasopharynx and can cause

254 Streptococcus pneumoniae (Spn) is an important Gram-positive human pat

255 Streptococcus pneumoniae (Spn) must acquire iron from the host to esta

256 zation of the nasopharynx with Streptococcus pneumoniae (Spn), although a prerequisite of infection,

257 In ovoid-shaped Streptococcus pneumoniae (Spn), septal and peripheral (elongation) PG

258 rbapenem-resistant strains of the Klebsiella pneumoniae ST258 (ref.

259 Five tailed bacteriophages against K pneumoniae ST258 clade 1 were selected for further chara

260 K. pneumoniae infection in mice; however, K. pneumoniae-stimulated reactive oxygen species (ROS) prod

261 y and increased neutrophil activation upon S pneumoniae stimulation.

262 , CM-13457, and CM-10455) and one Klebsiella pneumoniae strain (CM-11073) were grown overnight, seria

263 of secondary bacterial pneumonia with an S. pneumoniae strain that is innocuous to mice in the absen

264 esults for OXA-48 carbapenemase-producing K. pneumoniae strains (4 mug mL(-1)).

265 esistance in four diverse serum-resistant K. pneumoniae strains (NTUH-K2044, B5055, ATCC 43816, and R

266 ong antimicrobial activity toward several K. pneumoniae strains from a previously inactive peptide.

267 umonia caused by both group 1 and group 2 S. pneumoniae strains.

268 that retain activity against encapsulated K. pneumoniae, suggesting that this bacterial defense can b

269 oaches have advanced our understanding of K. pneumoniae taxonomy, ecology and evolution as well as th

270 We evaluate putative sources of K. pneumoniae that are carried by and infect hospital patie

271 2 were designated confirmed positives for M. pneumoniae The highest clinical sensitivities were found

272 Streptococcus pneumoniae (the pneumococcus) is a common nasopharyngeal

273 is, Chlamydophila pneumoniae, and Mycoplasma pneumoniae This multicenter evaluation provides data obt

274 hedding within feces, and transmission of K. pneumoniae through the fecal-oral route.

275 n, thereby enabling otherwise noninvasive S. pneumoniae to cause deadly pneumonia.

276 by serum enhances the capacity of Klebsiella pneumoniae to cause infection, but it is an incompletely

277 ic (Hypo) mice were infected with Klebsiella pneumoniae to determine infectious burden, immune cell a

278 clinical polymyxin-resistant (PR) Klebsiella pneumoniae to determine the molecular mechanisms of PR a

279 contributes positively to the ability of K. pneumoniae to form biofilms and adhere to different host

280 tic nasopharyngeal carriage of Streptococcus pneumoniae to invasive pneumococcal disease.

281 ed with an arrayed library of over 13,000 K. pneumoniae transposon insertion mutants in the lungs of

282 In vitro screens using a minilibrary of K. pneumoniae transposon mutants identified putative functi

283 isplayed this activity against capsulated K. pneumoniae Unexpectedly, the active peptide showed no de

284 or disrupting the protective barrier that K. pneumoniae uses to avoid the immune system and last-reso

285 ated pathogens, there is still no Klebsiella pneumoniae vaccine available.

286 with the 13-valent-conjugated Streptococcus pneumoniae vaccine were assessed in a MAIT cell activati

287 Africa sub-optimally interrupt Streptococcus pneumoniae vaccine-serotype (VT) carriage and transmissi

288 endent cytolysin (CDC) family, is a major S. pneumoniae virulence factor that generates ~25-nm diamet

289 To identify novel K. pneumoniae virulence factors needed to cause pneumonia,

290 ung infections in mice confirmed roles in K. pneumoniae virulence for the DeltadedA, DeltadsbC, Delta

291 entration (MIC) of RSM-932A and MN58b for S. pneumoniae was 0.4 muM and 10 muM, respectively, and the

292 Streptococcus pneumoniae was cultured in 33 episodes (51%) and H. infl

293 Klebsiella pneumoniae was isolated from cattle, poultry, hospital s

294 Klebsiella pneumoniae was isolated from stool of 17/149 (11%) patie

295 ecular epidemiological characteristics of M. pneumoniae We collected 446 M. pneumoniae-positive speci

296 the genome-reduced human pathogen Mycoplasma pneumoniae We combined whole-cell cross-linking mass spe

297 ica, Staphylococcus aureus and Streptococcus pneumoniae were also isolated.

298 Low levels of specific antibodies against S pneumoniae were found in 10 of 11 evaluated patients.

299 coccus spp., Escherichia coli and Klebsiella pneumoniae were the common bacterial pathogens that caus

300 Haemophilus influenzae and Streptococcus pneumoniae were the commonest bacterial pathogens detect